Tags

Type your tag names separated by a space and hit enter

Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population.
Exp Mol Pathol 2018; 104(1):50-58EM

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the accumulation of extra fat in liver cells not caused by alcohol. Elevated transaminase levels are common indicators of liver disease, including NAFLD. Previously, we demonstrated that PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), and GCKR (rs780094) are associated with elevated transaminase levels in overweight/obese Mexican adults. We investigated the association between 288 SNPs identified in genome-wide association studies and risk of elevated transaminase levels in an admixed Mexican-Mestizo sample of 178 cases of NAFLD and 454 healthy controls. The rs2896019, rs12483959, and rs3810622 SNPs in PNPLA3 and rs1227756 in COL13A1 were associated with elevated alanine aminotransferase (ALT, ≥40IU/L). A polygenic risk score (PRS) based on six SNPs in the ADIPOQ, COL13A1, PNPLA3, and SAMM50 genes was also associated with elevated ALT. Individuals carrying 9-12 risk alleles had 65.8% and 48.5% higher ALT and aspartate aminotransferase (AST) levels, respectively, than those with 1-4 risk alleles. The PRS showed the greatest risk of elevated ALT levels, with a higher level of significance than the individual variants. Our findings suggest a significant association between variants in COL13A1, ADIPOQ, SAMM50, and PNPLA3, and risk of NAFLD/elevated transaminase levels in Mexican adults with an admixed ancestry. This is the first study to examine high-density single nucleotide screening for genetic variations in a Mexican-Mestizo population. The extent of the effect of these variations on the development and progression of NAFLD in Latino populations requires further analysis.

Authors+Show Affiliations

Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico City, Mexico.Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social (IMSS), Blvd. Benito Juárez No. 31 Col. Centro, Cuernavaca, Morelos, Mexico; UCLA Department of Health Policy and Management, UCLA Kaiser Permanente Center for Health Equity, Fielding School of Public Health and Jonsson Comprehensive Cancer Center, Los Angeles, California, USA.Unidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, UNAM/Instituto Nacional de Medicina Genomica (INMEGEN), Mexico City, Mexico.Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social (IMSS), Blvd. Benito Juárez No. 31 Col. Centro, Cuernavaca, Morelos, Mexico.Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, Mexico.Consejo Nacional de Ciencia y Tecnología (CONACYT)-Laboratorio de Genómica del Metabolismo Óseo, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, México.Unidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, UNAM/Instituto Nacional de Medicina Genomica (INMEGEN), Mexico City, Mexico.Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social (IMSS), Blvd. Benito Juárez No. 31 Col. Centro, Cuernavaca, Morelos, Mexico.Clínica de Hígado, IMSS Hospital General Regional UMF, 1, Av. Plan de Ayala S/N, Cuernavaca, Morelos, Mexico.Unidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, UNAM/Instituto Nacional de Medicina Genomica (INMEGEN), Mexico City, Mexico.UCLA Department of Epidemiology, Fielding School of Public Health, Los Angeles, California, USA.Laboratorio de Genómica del Metabolismo Óseo, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social (IMSS), Blvd. Benito Juárez No. 31 Col. Centro, Cuernavaca, Morelos, Mexico; Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, Mexico.Laboratorio de Genómica del Metabolismo Óseo, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico. Electronic address: rvelazquez@inmegen.gob.mx.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

29307798

Citation

Larrieta-Carrasco, Elena, et al. "Genetic Variants in COL13A1, ADIPOQ and SAMM50, in Addition to the PNPLA3 Gene, Confer Susceptibility to Elevated Transaminase Levels in an Admixed Mexican Population." Experimental and Molecular Pathology, vol. 104, no. 1, 2018, pp. 50-58.
Larrieta-Carrasco E, Flores YN, Macías-Kauffer LR, et al. Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population. Exp Mol Pathol. 2018;104(1):50-58.
Larrieta-Carrasco, E., Flores, Y. N., Macías-Kauffer, L. R., Ramírez-Palacios, P., Quiterio, M., Ramírez-Salazar, E. G., ... Velázquez-Cruz, R. (2018). Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population. Experimental and Molecular Pathology, 104(1), pp. 50-58. doi:10.1016/j.yexmp.2018.01.001.
Larrieta-Carrasco E, et al. Genetic Variants in COL13A1, ADIPOQ and SAMM50, in Addition to the PNPLA3 Gene, Confer Susceptibility to Elevated Transaminase Levels in an Admixed Mexican Population. Exp Mol Pathol. 2018;104(1):50-58. PubMed PMID: 29307798.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population. AU - Larrieta-Carrasco,Elena, AU - Flores,Yvonne N, AU - Macías-Kauffer,Luis R, AU - Ramírez-Palacios,Paula, AU - Quiterio,Manuel, AU - Ramírez-Salazar,Eric G, AU - León-Mimila,Paola, AU - Rivera-Paredez,Berenice, AU - Cabrera-Álvarez,Guillermo, AU - Canizales-Quinteros,Samuel, AU - Zhang,Zuo-Feng, AU - López-Pérez,Tania V, AU - Salmerón,Jorge, AU - Velázquez-Cruz,Rafael, Y1 - 2018/01/04/ PY - 2017/06/21/received PY - 2017/11/15/revised PY - 2018/01/03/accepted PY - 2018/1/9/pubmed PY - 2018/10/3/medline PY - 2018/1/9/entrez KW - Alanine aminotransferase (ALT) KW - Aspartate aminotransferase (AST) KW - Mexican adults KW - Polygenic risk score KW - Polymorphisms SP - 50 EP - 58 JF - Experimental and molecular pathology JO - Exp. Mol. Pathol. VL - 104 IS - 1 N2 - Non-alcoholic fatty liver disease (NAFLD) is the accumulation of extra fat in liver cells not caused by alcohol. Elevated transaminase levels are common indicators of liver disease, including NAFLD. Previously, we demonstrated that PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), and GCKR (rs780094) are associated with elevated transaminase levels in overweight/obese Mexican adults. We investigated the association between 288 SNPs identified in genome-wide association studies and risk of elevated transaminase levels in an admixed Mexican-Mestizo sample of 178 cases of NAFLD and 454 healthy controls. The rs2896019, rs12483959, and rs3810622 SNPs in PNPLA3 and rs1227756 in COL13A1 were associated with elevated alanine aminotransferase (ALT, ≥40IU/L). A polygenic risk score (PRS) based on six SNPs in the ADIPOQ, COL13A1, PNPLA3, and SAMM50 genes was also associated with elevated ALT. Individuals carrying 9-12 risk alleles had 65.8% and 48.5% higher ALT and aspartate aminotransferase (AST) levels, respectively, than those with 1-4 risk alleles. The PRS showed the greatest risk of elevated ALT levels, with a higher level of significance than the individual variants. Our findings suggest a significant association between variants in COL13A1, ADIPOQ, SAMM50, and PNPLA3, and risk of NAFLD/elevated transaminase levels in Mexican adults with an admixed ancestry. This is the first study to examine high-density single nucleotide screening for genetic variations in a Mexican-Mestizo population. The extent of the effect of these variations on the development and progression of NAFLD in Latino populations requires further analysis. SN - 1096-0945 UR - https://www.unboundmedicine.com/medline/citation/29307798/Genetic_variants_in_COL13A1_ADIPOQ_and_SAMM50_in_addition_to_the_PNPLA3_gene_confer_susceptibility_to_elevated_transaminase_levels_in_an_admixed_Mexican_population_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-4800(17)30347-7 DB - PRIME DP - Unbound Medicine ER -